On April 7, 2021, Chardan hosted a leadership call featuring PDS Biotech (PDSB) management team moderated by Geulah Livshits, PhD, Senior Research Analyst.

Participating Management:
Frank Bedu-Addo, PhD, CEO
Seth Van Voorhees, PhD, CFO
Lauren Wood, MD, CMO

Listen to the replay of this event

Selected upcoming PDS Biotech catalysts:

●2Q-3Q21. PDS0101: Interim data from PDS Biotech-NCI Phase II combination study (NHS-IL12 & M7824) in advanced HPV-associated cancers

●2Q-3Q21. PDS0203: Initiation of PI/II study pending approval from Brazilian regulatory agency Anvisa

●4Q21-1Q22. PDS0101: Interim data from MDACC Phase II CRT combination study in advanced cervical cancer

●4Q21-1H22. PDS0101: Interim data from VERSATILE-002 trial in combination with Keytruda in 1L HNSCC

●4Q21-1Q22. PDS0203: Initiation of PIII study pending approval from Brazilian regulatory agency Anvisa

**This event is for current or prospective relationships of Chardan.